Denali Therapeutics
DNLI
292 hedge funds and large institutions have $4B invested in Denali Therapeutics in 2026 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 120 increasing their positions, 68 reducing their positions, and 28 closing their positions.
96% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 28
76% more repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 68
42% more capital invested
Capital invested by funds: $2.82B → $4B (+$1.18B)
9% more funds holding
Funds holding: 269 → 292 (+23)
5.48% more ownership
Funds ownership: 92.95% → 98.43% (+5.5%)
7% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $15.4M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$157M |
| 2 |
NAMI
Nomura Asset Management International
Philadelphia,
Pennsylvania
|
+$43M |
| 3 |
BNP Paribas Asset Management
Paris,
France
|
+$21.8M |
| 4 |
BlackRock
New York
|
+$20.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$38.4M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$35.4M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$34M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$26.1M |
| 5 |
DCM
Defilade Capital Management
Emeryville,
California
|
-$19.9M |
DNLI Hedge Fund Activity: Q2 2026 in Review
292 of the 8,298 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2026, worth a combined $4B — up 42% from $2.82B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new DNLI positions and 28 closed out — a net gain of 27 holders — while 120 added to existing stakes and 68 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $157M. The largest seller was Lynx1 Capital Management, cutting an estimated $38.4M.
- 292 institutional investors held Denali Therapeutics (DNLI) as of Q2 2026, up from 269 in Q1 2026.
- Funds reported $4B of Denali Therapeutics stock for Q2 2026, up 42% quarter-over-quarter.
- 55 funds opened new Denali Therapeutics positions in Q2 2026 and 28 closed out, a net change of +27 holders.
- The largest Denali Therapeutics buyer in Q2 2026 was T. Rowe Price Investment Management, an estimated $157M added.
- The largest Denali Therapeutics seller in Q2 2026 was Lynx1 Capital Management, an estimated $38.4M sold.
Based on aggregated 13F filings for Q2 2026.